What is NasaClip?
NasaClip is a specialized medical technology startup dedicated to revolutionizing the treatment of nosebleeds through innovative, hands-free device engineering. The company's core product integrates constant, uninterrupted external nasal pressure with medicated intranasal sponges, providing a dual-action approach to rapid hemostasis. By prioritizing patient comfort and clinical efficiency, NasaClip addresses the limitations of conventional, often cumbersome, epistaxis management methods. Positioned at the intersection of life sciences and consumer health, the firm is carving out a niche in the emergency and home-care medical device sectors, focusing on scalable solutions that improve patient outcomes while reducing the burden on clinical staff.
How much funding has NasaClip raised?
NasaClip has raised a total of $3.6M across 4 funding rounds:
Other Financing Round
$250K
Other Financing Round
$500K
Other Financing Round
$2.6M
Angel/Pre-Seed
$250K
Other Financing Round (2023): $250K with participation from Tedco
Other Financing Round (2023): $500K led by Tedco
Other Financing Round (2024): $2.6M, investors not publicly disclosed
Angel/Pre-Seed (2025): $250K featuring Tedco
Key Investors in NasaClip
Tedco
TEDCO, the Maryland Technology Development Corporation, enhances economic empowerment growth through the fostering of an inclusive entrepreneurial innovation ecosystem. TEDCO identifies, invests in, and helps grow technology and life science-based companies in Maryland.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for NasaClip?
Looking ahead, NasaClip is poised to leverage its recent capital influx to expand its clinical validation efforts and optimize its supply chain for broader distribution. The strategic roadmap includes scaling manufacturing capabilities to meet anticipated demand and pursuing regulatory milestones that will facilitate wider adoption in both clinical and consumer settings. As the company matures, the focus will likely shift toward establishing strategic partnerships with healthcare providers and distribution networks, ensuring that its painless, hands-free treatment becomes a standard of care for epistaxis management. The current funding environment provides the necessary runway for NasaClip to solidify its market position and continue its trajectory of innovation in the medical device landscape.
See full NasaClip company page
